Outlook Therapeutics provides update following FDA meeting on ONS-5010

Outlook Therapeutics (OTLK) provided an update following its recent Type A meeting with the FDA to discuss the December 30, 2025 complete response letter for the biologics license application, or BLA, for ONS-5010/Lytenava. The Type A meeting was conducted to clarify the outstanding issue identified in the CRL regarding substantial evidence of effectiveness and to discuss potential paths forward for regulatory approval. The company expects to continue engaging in discussions with the FDA to further clarify the Agency’s views on confirmatory evidence and the appropriate path forward. Outlook Therapeutics is evaluating the available regulatory options to advance ONS-5010 toward potential U.S. approval. “We appreciate the FDA’s engagement during the Type A meeting and remain committed to working constructively with the Agency,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Our goal is to reach alignment on the confirmatory evidence supporting our application and to identify the most efficient pathway toward potential approval.”